SymBio Pharma, Net Income Forecast for the Fiscal Year Loss Widened in Downward Revision

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Tue Jun 10, 2025 3:30 pm JST Revision

4582 SymBio Pharmaceuticals Limited 【J-GAAP】

Guidance Update Report

SymBio Pharmaceuticals Limited <4582> [TSE Growth] announced a performance revision after the market closed on June 10th (15:30). The consolidated net income/loss forecast for the fiscal year ending December 2025 has been revised downward from an expected loss of 4.46 billion yen to a loss of 4.59 billion yen (compared to a loss of 3.83 billion yen in the previous period), indicating an expansion in the loss margin. However, the full-year forecast for consolidated operating profit/loss has been revised upward from an expected loss of 4.26 billion yen to a loss of 4.26 billion yen (compared to a loss of 3.87 billion yen in the previous period), indicating a reduction in the loss margin.

Furthermore, The company continued to decline to disclose its earnings forecast for January to June (first half).

Kabutan News

Guidance Update

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2025 Prev	1,858	-4,263	-4,347	-4,468	-81.9	0	Feb 6, 2025	J-GAAP
Dec, 2025 New	1,400	-4,262	-4,467	-4,592	-84.2	0	Jun 10, 2025	J-GAAP
Revision Rate	-24.7%	+0.0%	-2.8%	-2.8%	-2.8%

Current Period Guidance

H1 Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jan - Jun, 2024	1,284	-1,719	-1,481	-1,541	-34.8	0	Aug 1, 2024	J-GAAP
Jan - Jun, 2025 Guidance	ー	ー	ー	ー	－	0	Feb 6, 2025	J-GAAP
YoY	－	－	－	－	－

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2023	5,589	-811	-736	-1,962	-49.2	0	Feb 8, 2024	J-GAAP
Dec, 2024	2,452	-3,876	-3,689	-3,833	-85.0	0	Feb 6, 2025	J-GAAP
Dec, 2025 Guidance	1,400	-4,262	-4,467	-4,592	-84.2	0	Jun 10, 2025	J-GAAP
YoY	-42.9%	-10.0%	-21.1%	-19.8%	+1.0%